

MediGene AG (MDG1) - Financial and Strategic SWOT Analysis Review

URL:	https://marketpublishers.com/r/M130417030AEN.html
Date:	June 28, 2017
Pages:	53
Price:	US\$ 125.00
ID:	M130417030AEN

MediGene AG (MDG1) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description – A detailed description of the company's operations and business divisions.
- Corporate strategy – Analyst's summarization of the company's business strategy.
- SWOT Analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives' employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

MediGene AG (MediGene) is a biotechnology company which develops drugs for the treatment of various types and stages of cancer with candidates in clinical and pre-clinical development. The company focuses on the development of personalized T-cell-based immunotherapies. Its core business develops three immunotherapy platforms such as DC vaccines to kill tumor cells; T-cell receptor (TCR) detect and efficiently kill tumor cells and T-cell-specific monoclonal antibodies (TAB's), helps to remove unwanted T cells from the body. MediGene also has one marketed drug, Veregen for the treatment of genital warts. The company has operational presence in US, Europe and Asia. Medigene is headquartered in Martinsried, Germany.

MediGene AG Key Recent Developments

May 11,2017: Medigene Reports Results Of First Quarter 2017

May 11,2017: Dave Lemus Steps Down As COO And Continues Cooperation In An Advisory Role

Mar 23,2017: Medigene publishes its 2016 annual report and outlook for 2017

Nov 22,2016: Medigene appoints Dr. Thomas Taapken as Chief Financial Officer

Nov 16,2016: Medigene highlights a new approach for neoantigen-specific TCRs at Neoantigen Summit 2016 in Boston

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

- The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Table of Content

SECTION 1 - ABOUT THE COMPANY

MediGene AG - Key Facts
MediGene AG - Key Employees
MediGene AG - Key Employee Biographies
MediGene AG - Major Products and Services
MediGene AG - History
MediGene AG - Company Statement
MediGene AG - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

MediGene AG - Business Description
MediGene AG - SWOT Analysis
SWOT Analysis - Overview
MediGene AG - Strengths
MediGene AG - Weaknesses
MediGene AG - Opportunities
MediGene AG - Threats
MediGene AG - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

MediGene AG, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
MediGene AG, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017
MediGene AG, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

May 11, 2017: Medigene Reports Results Of First Quarter 2017
May 11, 2017: Dave Lemus Steps Down As COO And Continues Cooperation In An Advisory Role
Mar 23, 2017: Medigene publishes its 2016 annual report and outlook for 2017
Nov 22, 2016: Medigene appoints Dr. Thomas Taapken as Chief Financial Officer
Nov 16, 2016: Medigene highlights a new approach for neoantigen-specific TCRs at Neoantigen Summit 2016 in Boston
Nov 10, 2016: Medigene reports its results for the first nine months of 2016
Sep 16, 2016: Medigene publicizes new bioinformatics tool to predict potential cross-reactivity of cancer and virus antigens
Aug 05, 2016: Medigene reports results of first six months 2016
Jul 25, 2016: Medigene expands TCR platform technology with US patent for method for identification of CD4+ T cell antigens
May 18, 2016: Medigene commissions EUFETS for cell production process for first own TCR studies

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

LIST OF TABLES

MediGene AG, Key Facts
MediGene AG, Key Employees
MediGene AG, Key Employee Biographies
MediGene AG, Major Products and Services

MediGene AG, History
MediGene AG, Subsidiaries
MediGene AG, Key Competitors
MediGene AG, Ratios based on current share price
MediGene AG, Annual Ratios
MediGene AG, Annual Ratios (Cont...1)
MediGene AG, Annual Ratios (Cont...2)
MediGene AG, Interim Ratios
MediGene AG, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
MediGene AG, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017
MediGene AG, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

LIST OF FIGURES

MediGene AG, Performance Chart (2012 - 2016)
MediGene AG, Ratio Charts
MediGene AG, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
MediGene AG, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017

COMPANIES MENTIONED

VITA 34 International AG
Tigo GmbH
Hemispherx Biopharma Inc
Genentech Inc
Ambrilia Biopharma Inc

I would like to order:

Product name: MediGene AG (MDG1) - Financial and Strategic SWOT Analysis Review
Product link: <https://marketpublishers.com/r/M130417030AEN.html>
Product ID: M130417030AEN
Price: US\$ 125.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service: office@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click 'BUY NOW' button on product page <https://marketpublishers.com/r/M130417030AEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
E-mail:
Company:
Address:
City:
Zip/Post Code:
Country:
Tel:
Fax:
Your message:

* All fields are required

Customer Signature _____

Please, note that by ordering from MarketPublisher.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms_conditions.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to **+44 20 7900 3970**